Audience has difficulty following presentation because student jumps around.
Student presents information in logical sequence which audience can follow.
Student presents information in logical, interesting sequence which audience can follow.
Subject Knowledge
Student does not have grasp of information; student cannot answer questions about subject.
-Student has a grasp of the project, understanding most of what was done and why.
-Student is uncomfortable with the information and is able to answer only rudimentary questions.
-Student has a grasp of the entire project understanding what was done.
-Student is at ease with expected answers to all questions, but fails to elaborate.
-Student demonstrates full knowledge (more than required) by understanding what was done and why.
-Answers all class questions with explanations and elaboration.
Graphics/ Slides
-Superfluous graphics or no graphics.
-Four or more spelling errors and/or grammatical errors.
-Font is too small and too much text on slides.
-Occasionally uses graphics that rarely support text and presentation.
-Has three misspellings and/or grammatical errors.
-Font is too small or too much text on slides.
-Graphics relate to text and presentation.
-No more than two misspellings and/or grammatical errors.
-Font size appropriate for reading with appropriate amount of text.
-Graphics explain and reinforce screen text and presentation.
-No misspellings or grammatical errors.
-Font is large enough to be seen by all and main points stand out.
Poise/Enthusiasm/ Eye Contact
-Reads slides/notes with no eye contact.
-Uncomfortable during entire presentation.
-Occasionally uses eye contact, but still reads slides/notes most of time.
-Uncomfortable at times.
-Maintains eye contact most of the time but frequently returns to slides/notes. -Generally relaxed.
-Maintains eye contact with audience, seldom returning to slides/notes. -Relaxed and confident.
Elocution/Pace
-Mumbles, incorrectly pronounces terms, and speaks too quietly for students in the back of class to hear.
-Monotone.
-Speaks too fast or slow for entire presentation.
-Voice is low. Work performed was incomplete and contributions were less than expected.
Work performed was useful and contributed to the final project.
Work performed was very useful and contributed significantly to the final project.
Team Attitude and Professionalism
Rarely had a positive attitude and treated others unprofessionally.
Usually had a positive attitude and treated others professionally.
Often had a positive attitude and treated others professionally.
Always had a positive attitude and treated others professionally. 
Team Cooperation and Communication

Quality of Work
Provides work that almost always needs to be checked/redone by others to ensure quality.
Provides work that often needs to be checked/redone by other group members to ensure quality.
Provides work that is of decent quality but occasionally needs to be checked/re-done by other group members to ensure top quality.
Provides high quality work.
Provides work of the highest quality.
Attitude
Often is publicly critical of the project or the work of other members of the group. Always has a negative attitude about the task(s).
Occasionally is publicly critical of the project or the work of other members of the group. Sometimes has a negative attitude about the task(s).
Occasionally is publicly critical of the project or the work of other members of the group. Usually has a positive attitude about the task(s).
Rarely is publicly critical of the project or the work of others. Usually has a positive attitude about the task(s).
Never is publicly critical of the project or the work of others. Always has a positive attitude about the task(s).
Preparedness Usually forgets needed materials and is rarely ready to get to work.
Brings needed materials about half of the time but is generally unorganized and has a hard time getting down to work.
Brings needed materials about half of the time but can usually get to working on the project.
Almost always brings needed materials and is usually ready to get to work.
Always brings needed materials and is always ready to work. 
Focus on the task
Grammar, Spelling, and Writing Mechanics
There are so many errors that the meaning is obscured.
The writing has many errors and distracts the reader.
There are occasional errors but they don't distract the reader or obscure the meaning.
The writing is free or almost free of errors.
Appendix 6: Example case study project description.
Veterinary Market for Vaccines against Insect Borne Viral Diseases
Background Arbovax, Inc. has a technology that can be used to make vaccines against any of the 700+ viruses transmitted by insects. The most important is Dengue Fever which is second only to Malaria in its global impact. There is, however, thought to be a significant market for such vaccines outside the field of human health. Diseases such as Eastern Equine Encephalitis affect both humans and animals. There are several good reasons to try and address this veterinary market, the regulatory pathway is simpler than for humans, it provides additional proof of principle and also contributes additional revenues.
Project
Initially the scope and size of the veterinary market needs to be investigated. In addition to horses, what other animals are affected by insect borne viruses. Are livestock animals at risk?
What are the insect-borne viral diseases that affect animals? When the market size has been estimated a value needs to be put on it.
What is the size of the market that can be addressed by this technology? We have four goals for this project: 1. Provide a list of arboviruses that are relevant in veterinary medicine, including background information about the diseases they cause. 2. Provide an overview of the state of the veterinary vaccine market. Identify potential revenues that could be generated from the production of vaccines for the viruses from Goal 1. 3. Rank the veterinary arboviruses according to the potential for Arbovax to have success in that respective market. 4. Identify the major companies involved in veterinary vaccines and provide an overview in their role in the market.
Work completed
To gain a clearer understanding of vaccines and arboviruses, we interviewed an immunologist and a virologist. We interviewed 3 veterinarians, an industry scientist, and a regulatory affairs manager to better understand unmet (and met) needs in the veterinary vaccine market. Finally, we interviewed an economist from NC State for insight into how we can determine the value of a vaccine market for each arbovirus.
Using information from the veterinarians we interviewed and independent research, we have developed an exhaustive list of arboviruses with a veterinary component and compiled information about their associated disease states. We consider Goal 1 to be complete.
We utilized the NC Biotech Center for our market/economic research: we have determined the current economic climate in countries where arboviruses are prevalent, and which qualities are favorable for potential markets. This information will factor in when we rank the potential market success for arbovirus vaccines.
We have developed a list of vaccines currently available to protect against arboviruses, including the cost of each per ml, and the required dosing regimen. This list is broken down by company, and there is a brief summary of each animal health company's role in the market. We consider Goal 4 to be complete.
We have determined the numbers of horses, cows, pigs, and sheep in some of the countries where arboviruses are prevalent. For the other countries where information is not as readily available, we will have to research a bit more creatively. The same holds true for the cost of losses due to each of the arboviruses.
Work awaiting completion
The two tasks that we will complete over the next two weeks are 1) organize the factors that we have discovered in our research, so that we can rank the arboviruses, and 2) identify potential revenues from a vaccine for each virus. The procedure for identifying potential revenues will vary depending on the specific virus in question. In some cases that may involve an understanding of the value of current vaccines on the market. In cases where there is no current vaccine, we must determine the number of animals that could potentially be vaccinated, the risk of disease for those animals, as well as how governmental policies will influence the use of the vaccine. Our goal is to have all research finished by April 6 th .
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Complications There have been no significant complications in the project at this time. The only foreseeable complication may be finding data about the potential revenues for vaccines in developing countries where record keeping may not be done consistently or be available. These factors will be taken into consideration when ranking vaccines for potential development. Arbovax's vaccine technology takes advantage of this fact by deleting amino acids from the membrane-spanning protein, rendering the virus incapable of producing infection in mammalian cells, but allowing it to reproduce freely in insect cells. The result is an ideal vaccine candidate: the virus can be grown in insect cells in its native conformation, and then introduced to mammalian immune systems with the same structure that the immune system would encounter in nature, without any perceptible risk of reversion to the infectious state. The result is strong immune protection while maintaining safety. This technology can, in principle, be applied to any of the enveloped arboviruses. Arbovax has received very promising data from primate trials on their Dengue vaccine, but have not yet taken any products to market.
The Problem: Arbovax is currently seeking entry into the veterinary vaccine market. With their technology, they expect to be a significant player in the field and appeal to large animal health firms with stable veterinary vaccine portfolios. The technology is well established, yet Arbovax is now faced with the task of selecting a virus for which to develop a vaccine. The goal is to develop a vaccine that will generate profit and place Arbovax in a high-profile position with evident partnering potential. Arbovax does not have any market research or significant experience in animal health, meaning that they need a general understanding of the organization of the industry as well as information about how their technology could fulfill unmet needs.
Research Methods:
The problem presented by Arbovax was incredibly open-ended, so before we could find answers we had to establish exactly what the question was. To learn more about the veterinary vaccine industry and arboviruses specifically, we interviewed professors at NC State including two immunologists, a virologist, an economist, and several members of the veterinary school. We were also able to utilize some contacts from the MMB board that work in animal health. These interviews provided the background we needed to focus our research on specific viruses of potential interest to Arbovax, as well as an understanding of the companies that play a prominent role in animal health.
Information was pulled from resources at the veterinary school library and NCSU online database on the viruses themselves. We found the library at the North Carolina Biotech Center incredibly helpful when it came to global market research and understanding the major trends that animal health companies are dealing with. Lastly, press releases and company websites provided information and current events, product pipelines, and costs for current vaccines on the market. Once this information was compiled, we weighed numerous factors to rank the potential arboviruses for pursuit by Arbovax. These factors included the following:
• Whether or not a current vaccine exists for a virus, and the quality of those vaccines if they do.
•
The geographic locations where the disease is a problem, and its potential to spread.
• The type of animal infected; feed animals compared to companion animals.
The potential to secure outside funding to pursue research.
Results and Company Recommendations:
Given the status of the current world market, projected spread of arthropod vector-borne viruses, and vaccination strategies currently employed by competitive products, we felt priority should be assigned to Eastern, Western, and Venezuelan Encephalitis. Currently sold as a combinatory product, several companies produce a single vaccination against the encephalitis', as well as West Nile Virus (WNV). Every horse in the United States is vaccinated for these diseases. The products consist mostly of killed viruses, and current practice involves at least a yearly vaccination. Veterinarians are in agreement that the current vaccines are inadequate. The Arbovax technology could confer a greater immune response by using a live virus, which would also mean the potential for one-time vaccination. As a secondary recommendation we believe Arbovax could also pursue a WNV vaccine, and therefore be able to produce a product that could completely replace the inferior vaccines on the market. Because there is a widely recognized need for an improved equine encephalitis vaccine and a steady current market it is a safe and logical way to enter into the veterinary vaccine industry. Relationships built as a result of such developments may open the door for the creation of vaccines with more complex market issues. We found that Merial, Pfizer, and Merck all produce equine encephalitis vaccines and could therefore be interested in a partnership to improve their current product.
We also believe that African Swine Fever (ASF) and Rift Valley Fever (RVF) could both be worth pursuit for Arbovax as long-term projects in the veterinary vaccine market. They are diseases that were traditionally considered endemic to sub-Saharan Africa, but are becoming emerging problems in Europe and the US. ASF has no current vaccine but the market for one is quite large considering devastating economic losses suffered in the last few years in Europe and Asia. Furthermore, the US government and countries in Western Europe consider it a potential national security threat and are concerned about the possibility of the disease spreading in animal feed. RVF does have a current vaccine available, but like the equine encephalitis vaccines it is considered insufficient. Currently the large animal health companies are not producing the RVF vaccine, but Texas A&M University and a smaller firm named GALVmed are working in that area.
What We Learned:
The case study project with Arbovax was valuable in that it allowed us to use our business knowledge to investigate the market for insect-borne viral diseases and deliver useful results. Not only were we able to meet the goals of the project, but our information has helped broaden Arbovax's considerations for promising investment viruses. Through our research we learned about the key players in the market and the disease states they are targeting, emerging diseases outside of the U.S. that may be of concern to Arbovax and well-understood disease states that require consistent treatment/vaccination. It was a pleasure working with the group who seemed to be involved and enjoying the project. 
Final Written Deliverable (30 pts)
